Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
3(75.0%)
N/A
1(25.0%)
4Total
Phase 1(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04521413Phase 1Active Not Recruiting

Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

Role: lead

NCT04730258Phase 1Active Not Recruiting

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

Role: lead

NCT05251714Phase 1Active Not Recruiting

CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

Role: lead

NCT03891641Not ApplicableTerminated

Momentum-enabled Treadling Methodology to Improve Gait and Enhance Mobility

Role: collaborator

All 4 trials loaded